|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Ursodiol
Description of Ursodiol:
ursodiol is a
synthetically-derived form of ursodiol, a bile acid produced by the
liver and secreted and stored in the gallbladder. Also produced by the
Chinese black bear liver, ursodiol has been used in the treatment of
liver disease for centuries. This agent dissolves or prevents
cholesterol gallstones by blocking hepatic cholesterol production and
decreasing bile cholesterol. Ursodiol also reduces the absorption of
cholesterol from the intestinal tract. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
|
MedKoo Code#: 203091
|
|
Name: Ursodiol
|
|
CAS#: 128-13-2
Synonym:
ursodeoxycholic acid. US brand names: Actigall; URSO. Foreign
brand name: Deursil; Actigall, Ursosan, Ursofalk, Urso, and Urso
Forte.
IUPAC/Chemical name:
(R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic
acid
|
|
Chemical structure |
Theoretical analysis
|
|
|
MedKoo Code#: 203091
Name: Ursodiol
CAS#: 128-13-2
Chemical Formula: C24H40O4
Exact Mass: 392.29266
Molecular Weight: 392.57
Elemental Analysis: C, 73.43; H, 10.27; O,
16.30
|
|
Availability and price:
This agent is not in stock, which may be available through custom synthesis.
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Information about this agent
|
Ursodiol, also known as ursodeoxycholic acid and the
abbreviation UDCA, is one of the secondary bile acids, which are
metabolic byproducts of intestinal bacteria.
Ursodeoxycholic acid goes by the trade names Actigall,
Ursosan, Ursofalk, Urso, and Urso Forte. In Italy and Switzerland, it is
marketed under the name Deursil. Ursodeoxycholic acid can be chemically
synthesized and was brought to market by the Montreal-based Axcan Pharma
in 1998, which continues to market the drug. The drug reduces
cholesterol absorption and is used to dissolve (cholesterol) gallstones
in patients who want an alternative to surgery. The drug is very
expensive, however, and if the patient stops taking it, the gallstones
tend to recur if the condition that gave rise to their formation does
not change. For these reasons, it has not supplanted surgical treatment
by cholecystectomy. It is the only FDA approved drug to treat
primary biliary cirrhosis. See:
http://en.wikipedia.org/wiki/Ursodiol.
Current developer:
1: Geiger CM, Voudrie MA 2nd, Sorenson B. Stability
of ursodiol in SyrSpend SF Cherry flavored. Int J Pharm Compd. 2012
Nov-Dec;16(6):510-2. PubMed PMID: 23259368.
2: Leung J, Bonis PA, Kaplan MM. Colchicine or methotrexate, with
ursodiol, are effective after 20 years in a subset of patients with
primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2011
Sep;9(9):776-80. doi: 10.1016/j.cgh.2011.05.010. Epub 2011 May 20.
PubMed PMID: 21699802.
3: Lakshminarayanan S, Sahdev I, Goyal M, Vlachos A, Atlas M, Lipton JM.
Low incidence of hepatic veno-occlusive disease in pediatric patients
undergoing hematopoietic stem cell transplantation attributed to a
combination of intravenous heparin, oral glutamine, and ursodiol at a
single transplant institution. Pediatr Transplant. 2010
Aug;14(5):618-21. doi: 10.1111/j.1399-3046.2009.01285.x. Epub 2009 Dec
30. PubMed PMID: 20051023.
4: Kaplan MM, Poupon R. Treatment with immunosuppressives in patients
with primary biliary cirrhosis who fail to respond to ursodiol.
Hepatology. 2009 Aug;50(2):652. doi: 10.1002/hep.22831. PubMed PMID:
19309721.
5: Mason AL, Lindor KD, Bacon BR, Vincent C, Neuberger JM, Wasilenko ST.
Clinical Trial: Randomized controlled trial of zidovudine and lamivudine
for patients with primary biliary cirrhosis stabilized on ursodiol.
Aliment Pharmacol Ther. 2008 Jul 9. [Epub ahead of print] PubMed PMID:
18627363.
6: San Luis VA, Btaiche IF. Ursodiol in patients with parenteral
nutrition-associated cholestasis. Ann Pharmacother. 2007
Nov;41(11):1867-72. Epub 2007 Oct 2. Review. PubMed PMID: 17911205.
7: Suskind DL, Finn L, Wahbeh G, Christie D, Horslen S. A child with
Kabuki syndrome and primary sclerosing cholangitis successfully treated
with ursodiol and cholestryamine. J Pediatr Gastroenterol Nutr. 2006
Oct;43(4):542-4. PubMed PMID: 17033534.
8: Goodwin R, Hannum J, Clark R. Overdose of ursodiol in preterm infant
is well tolerated. Pediatr Emerg Care. 2006 Aug;22(8):619. PubMed PMID:
16912636.
9: Sundd Singh S, Shah H, Gupta S, Jain M, Sharma K, Patel H, Shah B,
Thakkar P, Patel N, Shah R, Bhushan Lohary B. Validation of LC/MS
electrospray ionisation method for the estimation of ursodiol in human
plasma and its application in bioequivalence study. Ann Chim. 2004
Dec;94(12):951-9. PubMed PMID: 15689031.
10: Tarao K, Fujiyama S, Ohkawa S, Miyakawa K, Tamai S, Hirokawa S,
Masaki T, Tanaka K. Ursodiol use is possibly associated with lower
incidence of hepatocellular carcinoma in hepatitis C virus-associated
liver cirrhosis. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):164-9.
PubMed PMID: 15668491.
11: Kaplan MM, Cheng S, Price LL, Bonis PA. A randomized controlled
trial of colchicine plus ursodiol versus methotrexate plus ursodiol in
primary biliary cirrhosis: ten-year results. Hepatology. 2004
Apr;39(4):915-23. PubMed PMID: 15057894.
12: Brentnall T. UC for UC: ursodiol chemoprevention for ulcerative
colitis. Inflamm Bowel Dis. 2003 Sep;9(5):338. PubMed PMID: 14570007.
13: Scott DJ, Villegas L, Sims TL, Hamilton EC, Provost DA, Jones DB.
Intraoperative ultrasound and prophylactic ursodiol for gallstone
prevention following laparoscopic gastric bypass. Surg Endosc. 2003
Nov;17(11):1796-802. Epub 2003 Sep 10. PubMed PMID: 12958683.
14: Cadranel JF, Di Martino V, Dorent R, Bernard B, Hoang C, Myara A,
Pauwels A, Ghoussoub JJ, Perrin M, Grippon P, Thabut D, Trivin F, Huraux
JM, Gandjbakhch I, Opolon P, Lunel F. Effects of ursodeoxycholic acid (ursodiol)
treatment on chronic viral hepatitis in heart transplant patients:
results of a prospective, double-blind, placebo-randomized study.
Transplantation. 2003 Apr 15;75(7):977-82. PubMed PMID: 12698083.
15: Brentnall TA. Ursodiol: good drug makes good. Gastroenterology. 2003
Apr;124(4):1139-40. Review. PubMed PMID: 12671906.
16: Lee YM, Kaplan MM. Efficacy of colchicine in patients with primary
biliary cirrhosis poorly responsive to ursodiol and methotrexate. Am J
Gastroenterol. 2003 Jan;98(1):205-8. PubMed PMID: 12526960.
17: Jorgensen R, Angulo P, Dickson ER, Lindor KD. Results of long-term
ursodiol treatment for patients with primary biliary cirrhosis. Am J
Gastroenterol. 2002 Oct;97(10):2647-50. PubMed PMID: 12385454.
18: Giles F, Garcia-Manero G, Cortes J, Thomas D, Kantarjian H, Estey E.
Ursodiol does not prevent hepatic venoocclusive disease associated with
Mylotarg therapy. Haematologica. 2002 Oct;87(10):1114-6. PubMed PMID:
12368170.
19: Johnson CE, Streetman DD. Stability of oral suspensions of ursodiol
made from tablets. Am J Health Syst Pharm. 2002 Feb 15;59(4):361-3.
PubMed PMID: 11885400.
20: Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary
cirrhosis: incidence and predictive factors of cirrhosis development in
ursodiol-treated patients. Gastroenterology. 2002 Mar;122(3):652-8.
PubMed PMID: 11874998.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
